Skip to main content
OpenTrials
Completed

NCT Number: NCT05629780

Temporal Changes of Lactate in CLASSIC Patients

This study aim to examine if randomization to different treatment strategies had any effect on the time to normalization of lactate in intensive care patients treated for septic shock.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Karolinska University Hospital

Stockholm, 14186, Sweden

About this study

This is a retrospective analysis of a subset of patients included in the Conservative versus Liberal Approach to fluid therapy of Septic Shock in Intensive Care (CLASSIC) trial.

In the CLASSIC trial patients with septic shock were randomized to either traditional (liberal) strategy for fluid treatment or a more conservative regimen. The study was an international multicenter clinical trial (clinicaltrials.gov NCT03668236), and results were published in New England Journal of Medicine in June 2022 (DOI: 10.1056/NEJMoa2202707).

In this substudy the investigator extract all lactate values for the study period from all patients included from Karolinska University Hospital, Sundsvall and Södersjukhuset (Sweden), participating centers on Zealand (Denmark), and Plzen University Hospital (Czech Republic). Baseline data, treatment allocation and amount of fluids administered are collected as well as outcome from CLASSIC study.

Primary outcome is time to lactate normalization (< 2mmol/L). Secondary outcome is lactate concentration over the first 72 hours (as peak lactate for the time intervals 0-3, 3-6, 6-12, 12-24 and then each 12h-period between 24 and 72 hours).

The subgroup with blood lactate > 4mmol/L will be analyzed separately for the same end points.

Time to resolution of hyperlactatemia will be modelled with a competing risks regression. Death and discharge will be competing outcomes, and administrative censoring imposed 72 hours after randomisation.

Factors associated with time to lactate normalization will be examined through regression analysis. Factors that show a relationship on univariate analysis will be included in a multivariate analysis.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participation in CLASSIC trial in any of the participating centres

Exclusion criteria

  • Lack of sufficient data for analysis

Treatment and study plan

Resuscitation fluid

Drug

Cristalloid fluids given as a resuscitational intervention

Primary outcomes

  1. Time to resolution of hyperlactemia

    Time frame: 72 hours

    Blood lactate < 2.0 mmol/L

Secondary outcomes

  1. Temporal changes in lactate concentrations over time

    Time frame: 72 hours

    Difference in blood lactate at during the first 72h from enrollment

Sponsors and collaborators

Lead sponsor

Karolinska University Hospital

Other

Collaborators

  • Collabortation for Research in Intensive Care (CRIC)
  • European Society of Intensive Care Medicine
  • Region Stockholm
  • The Scandinavian Society of Anaesthesiology and Intensive Care Medicine (SSAI)

Registry information

Official study title

Temporal Changes in Plasma Lactate Concentration in Critically Ill Patients With Septic Shock Treated With Restrictive Compared to Standard Fluid Therapy

Important dates

Study start
2022
Primary completion
2022
Study completion
2023
First posted
Nov 29, 2022
Registry last updated
Sep 14, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.